News

R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.

This partnership will allow IRIS to license AEYE Diagnostic Screening (AEYE-DS), an FDA-cleared AI technology for autonomous detection of diabetic retinopathy (DR).

Apellis has announced that seven abstracts will be presented at the American Society of Retina Specialists Annual Scientific Meeting including safety and efficacy data for the company’s pegcetacoplan injection for geographic atrophy (GA).

According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.

The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.

The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.

ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.

Vantage Surgical Solutions has acquired Ophthalmic Surgical Solutions (OSS). OSS is a Kansas-based company specializing in ophthalmic surgical equipment and services.

The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.

The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.

The skills highlighted during the session are some of the most important tools in an ophthalmologist’s toolbelt and learning and practicing them early, even as a medical student, is crucial.

The London-based company will use regenerative medicine to fight ocular disease.

The Kansas-based company specializes in ophthalmic surgical equipment and services.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.

ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

According to the companies, R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery. It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells.

According to the company, VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg.

Researchers found that better general health and ability to drive were each separately associated with significantly lower risk of death among individuals with AMD.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

Naor is stepping down to pursue new opportunities and will be replaced by Kenneth Sall, MD who has been appointed as Opthea’s Senior Medical Advisor.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.